Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Risk of Tuberculosis Infection in Young Children Exposed to Multidrug-resistant Tuberculosis in the TB-CHAMP Multi-site Randomized Controlled Trial.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Screening and tuberculosis preventive treatment among household contacts of drug-resistant tuberculosis patients: a scoping review.BMC infectious diseases · 2026Article
- Experiences from Ukraine in expanding TB infection diagnosis and treatment, including for drug-resistant TB.IJTLD open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundYoung children have a high risk of developing tuberculosis (TB) disease following infection with Mycobacterium tuberculosis in the absence of preventive treatment. Infection prevalence and risk factors for infection impact delivery of prevention strategies. We aimed to determine the prevalence of infection in child household contacts aged <5 years exposed to adults with confirmed pulmonary multidrug-resistant (MDR)-TB and to determine risk factors for infection.
methodsTB-CHAMP was a trial of MDR-TB prevention that recruited children younger than age 5 years, regardless of M. tuberculosis infection status. All children enrolled had an interferon-gamma release assay (IGRA) at baseline. We described M. tuberculosis infection prevalence, developed directed acyclic graphs to clarify causal relationships, and used modified Poisson regression models to assess the relationship between risk factors and IGRA positivity.
resultsOf 785 included children, 160 (20.4%) had a positive IGRA. Duration of cough and drug misuse in the index patient, age of the child, relationship between the child and the index patient, and study site were significantly associated with risk of infection.
conclusionsThe prevalence of infection was lower than observed in previous studies. This may be related to improved diagnosis and treatment of MDR-TB in the study setting and/or test limitations and has implications for TB preventive treatment. When considering TB preventive treatment for child contacts, healthcare providers should be especially concerned about any young child exposed to an adult index patient who is his/her parent/primary caregiver, has a chronic cough, and/or a history of drug misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.